COMMUNIQUÉS West-GlobeNewswire

Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)
03/12/2018
U.S. launch scheduled for early in the first quarter of 2019 Catalyst is well-capitalized and sees no current need for capital infusion CORAL GABLES, Fla., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc [...]
Nuvectra Receives FDA Head-Only MR-Conditional Approval for Algovita®
03/12/2018
PLANO, Texas, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) head-only MR- [...]
Selecta Biosciences Announces New Employment Inducement Grants
03/12/2018
WATERTOWN, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]
GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
03/12/2018
Pre-NDA Meeting to be Requested for First Quarter of 2019 Company to Host Conference Call and Webcast Today, Monday, December 3, at 5:30 a.m. PT/8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE [...]
Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition
03/12/2018
BERKELEY, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data in two abstracts for its first-in-class anti-APRIL antibody BION-1301 supporting its potential use [...]
Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors
03/12/2018
ROCKVILLE, Md., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that [...]
Study of Feraheme demonstrates Improvements in Fatigue and Quality Of Life in Iron Deficiency Anemia Patients
03/12/2018
Key Findings of a 6-Month Extension Study Presented at the American Society of Hematology Annual Meeting WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that [...]
Tabula Rasa HealthCare to Acquire DoseMe, a Precision Dosing Software Company
03/12/2018
Acquisition projected to expand reach of TRHC’s medication safety technologies in the hospital healthcare system market and internationally MOORESTOWN, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc [...]
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
03/12/2018
LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, [...]
LogicBio Reports Third Quarter 2018 Financial Results
03/12/2018
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in [...]
Tetra Natural Health Will Deliver 20 containers of Hemp Energy Drink to Meet Consumer Demand
03/12/2018
ORLEANS, Ontario, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its [...]
Tetra Santé Naturelle livrera 20 conteneurs de Hemp Energy Drink pour répondre à la demande
03/12/2018
ORLEANS, Ontario, 03 déc. 2018 (GLOBE NEWSWIRE) -- Tetra Santé Naturelle, une filiale de Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), annonce la livraison de vingt (20) conteneurs, soit plus de 1,7 millions de [...]
Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data
03/12/2018
JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance [...]
Nephros to Present at the 11th Annual LD Micro Main Event
03/12/2018
Presentation Scheduled for 9:30 AM PT on Tuesday, December 4th SOUTH ORANGE, NJ, Dec. 03, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (OTCQB: NEPH) (“Nephros”), a commercial stage medical device company [...]
Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
03/12/2018
Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients, including Complete Remission (CR) rate of 34% ORR of 54% and CR/Partial Response (PR) [...]
Theratechnologies Appoints New Chief Commercial Officer
03/12/2018
MONTREAL, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce the appointment of Mr. Jovan Antunovic as Senior Vice President and Chief Commercial Officer. “ [...]
Theratechnologies nomme un nouveau chef de l’exploitation commerciale
03/12/2018
MONTRÉAL, 03 déc. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer la nomination de M. Jovan Antunovic à titre de vice-président principal et chef de l’exploitation [...]
Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting
03/12/2018
XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9 am ET Today BURNABY, [...]
Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product
03/12/2018
Expands medical device production capabilities SAN DIEGO and TOKYO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced that the Company has received approval [...]

Pages